- Report
- August 2024
- 80 Pages
Japan
From €3077EUR$3,500USD£2,680GBP
- Report
- August 2023
- 117 Pages
Global
From €3956EUR$4,500USD£3,446GBP
- Report
- February 2024
- 115 Pages
Global
From €4175EUR$4,750USD£3,637GBP
- Report
- April 2023
- 111 Pages
Global
From €4175EUR$4,750USD£3,637GBP
- Report
- May 2024
- 327 Pages
Global
From €3516EUR$4,000USD£3,063GBP
- Report
- July 2024
- 100 Pages
Global
From €2637EUR$3,000USD£2,297GBP
€3296EUR$3,750USD£2,872GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €3481EUR$3,960USD£3,033GBP
€4351EUR$4,950USD£3,791GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €3481EUR$3,960USD£3,033GBP
€4351EUR$4,950USD£3,791GBP
- Report
- January 2024
- 200 Pages
Global
From €3648EUR$4,150USD£3,178GBP
- Report
- August 2023
- 145 Pages
Global
From €2769EUR$3,150USD£2,412GBP
- Report
- July 2023
- 141 Pages
Asia Pacific
From €1319EUR$1,500USD£1,149GBP
- Report
- July 2023
- 128 Pages
North America
From €1319EUR$1,500USD£1,149GBP
- Report
- July 2023
- 139 Pages
Europe
From €1319EUR$1,500USD£1,149GBP
- Report
- July 2023
- 142 Pages
Africa, Middle East
From €1319EUR$1,500USD£1,149GBP
- Report
- February 2024
- 120 Pages
Global
From €4175EUR$4,750USD£3,637GBP
- Report
- March 2023
- 209 Pages
Global
From €3912EUR$4,450USD£3,408GBP
- Report
- April 2024
- 121 Pages
Global
From €3472EUR$3,950USD£3,025GBP
- Report
- November 2023
- 150 Pages
Global
From €3384EUR$3,850USD£2,948GBP
€4263EUR$4,850USD£3,714GBP
- Report
- December 2023
- 143 Pages
Global
From €3912EUR$4,450USD£3,408GBP
- Report
- September 2024
- 250 Pages
Global
From €4350EUR$4,949USD£3,790GBP

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more